INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Principal Officers. |
Agreement>
into an amendment to Limiteds Executive Service Agreement, dated
July 27, 2016 between Limited and Alistair Macdonald, the Chief
Executive Officer of Limited and its parent company, INC Research
Holdings, Inc. (the Company) and a member of the Board of
Directors of the Company (the Amendment). The Amendment revises
Mr. Macdonalds U.K. pension entitlements in compliance with U.K.
pension regulations, provides for an annual travel allowance and
provides Mr. Macdonald with severance entitlements that are
consistent with the severance entitlements that other executive
officers of the Company receive under the Companys Executive
Severance Plan.
resigns for good reason (other than as described in the next
sentence), then he will receive a cash severance payment equal to
two times his base salary and 12 months of health care coverage
continuation. If Mr. Macdonald is terminated without cause or he
resigns for good reason during the period commencing three months
prior to and ending 24 months after a change in control of the
Company, then he will receive a cash severance payment equal to
three times his base salary plus one times his target bonus, 12
months of health care coverage continuation and full vesting of
any outstanding equity awards.
entirety by reference to the agreement itself, which is attached
to the Current Report as Exhibit 10.1 and which is incorporated
by reference in its entirety into this Item 5.02.
|
Exhibit No.
|
Description
|
|
10.1
|
Amendment One to the Executive Service Agreement,
effective as of April 1, 2017, between INC Research Holding Limited and Alistair Macdonald. |
About INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Recent Trading Information
INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) closed its last trading session down -0.40 at 44.25 with 1,112,195 shares trading hands.